EGFR Target Therapy Combined with Gemox for Advanced Biliary Tract Cancers: a Meta-analysis based on RCTs

Conclusion: GEMOX + EGFR-targeted therapy is a considerable and tolerable treatment option for patients with advanced BTCs, improving both PFS and ORR but not prolonging patient survival. Patients with cholangiocarcinoma would benefit the most from EGFR-targeted therapy.

Source: Journal of Cancer - June 20, 2018 Category: Cancer & Oncology Authors: Wen Cai, Ying Yuan, Weiting Ge, Yu Fan, Xue Liu, Dehao Wu, Hanguang Hu Tags: Research Paper Source Type: research